UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Selexipag for the Treatment of Pulmonary Arterial Hypertension

The New England journal of medicine, 2015-12, Vol.373 (26), p.2522-2533

2015

Volltextzugriff (PDF)

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

American journal of respiratory and critical care medicine, 2008-10, Vol.178 (7), p.729-737

2008

Volltextzugriff (PDF)

Left atrial structure and function and clinical outcomes in the general population

European heart journal, 2013-01, Vol.34 (4), p.278-285

2013

Volltextzugriff (PDF)

Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?

Chest, 2006-12, Vol.130 (6), p.1657-1663

2006

Volltextzugriff (PDF)

The right ventricle in pulmonary hypertension

Coronary artery disease, 2005-02, Vol.16 (1), p.13-18

2005

Volltextzugriff (PDF)

Pregnancy and Congenital Heart Disease–Associated Pulmonary Hypertension: Are Outcomes Improving?

Circulation (New York, N.Y.), 2023-02, Vol.147 (7), p.562-564

2023

Volltextzugriff (PDF)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Respiratory research, 2021-02, Vol.22 (1), p.34-9, Article 34

2021

Volltextzugriff (PDF)

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Cardiology and therapy, 2024-06, Vol.13 (2), p.315-339

2024

Volltextzugriff (PDF)

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Pulmonary therapy, 2024-03, Vol.10 (1), p.85-107

2024

Volltextzugriff (PDF)

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

Pulmonary circulation, 2020-10, Vol.10 (4), p.1-4

2020

Volltextzugriff (PDF)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

ERJ open research, 2023-01, Vol.9 (1), p.456-2022

2023

Volltextzugriff (PDF)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Pulmonary circulation, 2023-04, Vol.13 (2), p.e12226-n/a

2023

Volltextzugriff (PDF)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary circulation, 2022-10, Vol.12 (4), p.e12150-n/a

2022

Volltextzugriff (PDF)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Pulmonary circulation, 2020-04, Vol.10 (2), p.1-9

2020

Volltextzugriff (PDF)

Telomere shortening in familial and sporadic pulmonary fibrosis

American journal of respiratory and critical care medicine, 2008-10, Vol.178 (7), p.729-737

2008

Volltextzugriff (PDF)

Lessons from the COMPASS-3 Study

Pulmonary circulation, 2018-01, Vol.8 (1), p.1-3

2018

Volltextzugriff (PDF)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2440-2450

2019

Volltextzugriff (PDF)

Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis

Circulation. Heart failure, 2015-11, Vol.8 (6), p.1032-1043

2015

Volltextzugriff (PDF)

Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study

Chest, 2022-09, Vol.162 (3), p.669-683

2022

Volltextzugriff (PDF)

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

The European respiratory journal, 2024-09, Vol.64 (5), p.2401110

2024

Volltextzugriff (PDF)

Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension

Chest, 2009-01, Vol.135 (1), p.130-136

2009

Volltextzugriff (PDF)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

European journal of heart failure, 2022-01, Vol.24 (1), p.205-214

2022

Volltextzugriff (PDF)

Treatment algorithm for pulmonary arterial hypertension

The European respiratory journal, 2024-10, Vol.64 (4), p.2401325

2024

Volltextzugriff (PDF)

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Chest, 2018-09, Vol.154 (3), p.532-540

2018

Volltextzugriff (PDF)

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Chest, 2021-07, Vol.160 (1), p.277-286

2021

Volltextzugriff (PDF)

1 – 25 von 240

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(201)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Selexipag for the Treatment of Pulmonary Arterial Hypertension

Telomere Shortening in Familial and Sporadic Pulmonary Fibrosis

Left atrial structure and function and clinical outcomes in the general population

Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?

The right ventricle in pulmonary hypertension

Pregnancy and Congenital Heart Disease–Associated Pulmonary Hypertension: Are Outcomes Improving?

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

Safety of Macitentan for the Treatment of Portopulmonary Hypertension: Real-World Evidence from the Combined OPUS/OrPHeUS Studies

Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)

Pulmonary Arterial Hypertension—Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting

Telomere shortening in familial and sporadic pulmonary fibrosis

Lessons from the COMPASS-3 Study

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study

Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis

Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study

MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study

Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

Treatment algorithm for pulmonary arterial hypertension

Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids

Relationship Between Time From Diagnosis and Morbidity or Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study

Aktive Filter

Suchergebnisse filtern